BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY JOINT VENTURE WITH DNX
Executive Summary
BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY JOINT VENTURE WITH DNX, the companies announced Aug. 30. The new entity, Nextran, will seek to develop and commercialize technologies "to improve the success and increase the availability of organ transplantation." Under the terms of the agreement, Baxter will own 70% of Nextran and Princeton, N.J.-based DNX will hold 30% of the firm. Nextran will operate as an affiliate of Baxter.